Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest?

Publication date: January–February 2019Source: Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume 13, Issue 1Author(s): S. Gentile, F. Strollo, G. Guarino, C. Brancario, M. Corigliano, G. Cozzolino, M.R. Improta, A. Fasolino, C. Lamberti, M. Lapice, C. Martino, D. Oliva, A. Raffaele, A. Selleri, R. Simonetti, A. Stile, A. Vecchiato, A. Vetrano, P. Volpe, G. CaputoAbstractLipohypertophy (LH) is the most common skin complication of incorrect injection technique which does not only represent an aesthetic defect but also severely disrupts insulin pharmacokinetics/pharmacodynamics. As a consequence of that, hormone release is delayed and unexplained/unpredictable hypoglycemia occurs, both deteriorating metabolic control while negatively affecting adherence to treatment and quality of life. The economic burden due to unwanted intra-LH injections is accounted for by inappropriately high insulin requirements, increased emergency-related hospitalizations, and loss of work days. Greater attention has to be paid by diabetes care teams to education programs with periodic refreshers to achieve better metabolic control and reduce the economic burden of diabetes.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research